These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30592080)

  • 1. Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study.
    Hamlin PA; Flinn IW; Wagner-Johnston N; Burger JA; Coffey GP; Conley PB; Michelson G; Leeds JM; Der K; Kim Y; Sabalvaro-Torres A; Birrell M; Pandey A; Curnutte JT; Patel MR
    Am J Hematol; 2019 Apr; 94(4):E90-E93. PubMed ID: 30592080
    [No Abstract]   [Full Text] [Related]  

  • 2. Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies.
    Coffey GP; Feng J; Betz A; Pandey A; Birrell M; Leeds JM; Der K; Kadri S; Lu P; Segal J; Wang YL; Michelson G; Curnutte JT; Conley PB
    Clin Cancer Res; 2019 Feb; 25(4):1174-1184. PubMed ID: 30333224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-adult T‑cell leukemia/lymphoma activity of cerdulatinib, a dual SYK/JAK kinase inhibitor.
    Ishikawa C; Senba M; Mori N
    Int J Oncol; 2018 Oct; 53(4):1681-1690. PubMed ID: 30066853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.
    Blunt MD; Koehrer S; Dobson RC; Larrayoz M; Wilmore S; Hayman A; Parnell J; Smith LD; Davies A; Johnson PWM; Conley PB; Pandey A; Strefford JC; Stevenson FK; Packham G; Forconi F; Coffey GP; Burger JA; Steele AJ
    Clin Cancer Res; 2017 May; 23(9):2313-2324. PubMed ID: 27697994
    [No Abstract]   [Full Text] [Related]  

  • 5. Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma.
    Ma J; Xing W; Coffey G; Dresser K; Lu K; Guo A; Raca G; Pandey A; Conley P; Yu H; Wang YL
    Oncotarget; 2015 Dec; 6(41):43881-96. PubMed ID: 26575169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.
    Coffey G; Betz A; DeGuzman F; Pak Y; Inagaki M; Baker DC; Hollenbach SJ; Pandey A; Sinha U
    J Pharmacol Exp Ther; 2014 Dec; 351(3):538-48. PubMed ID: 25253883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Syk inhibitors in clinical development for hematological malignancies.
    Liu D; Mamorska-Dyga A
    J Hematol Oncol; 2017 Jul; 10(1):145. PubMed ID: 28754125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK).
    Lam B; Arikawa Y; Cramlett J; Dong Q; de Jong R; Feher V; Grimshaw CE; Farrell PJ; Hoffman ID; Jennings A; Jones B; Matuszkiewicz J; Miura J; Miyake H; Natala SR; Shi L; Takahashi M; Taylor E; Wyrick C; Yano J; Zalevsky J; Nie Z
    Bioorg Med Chem Lett; 2016 Dec; 26(24):5947-5950. PubMed ID: 27839918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 1b, Randomized, Single-Center Trial of Topical Cerdulatinib (DMVT-502) in Patients with Mild-to-Moderate Atopic Dermatitis.
    Piscitelli SC; Pavel AB; McHale K; Jett JE; Collins J; Gillmor D; Tabolt G; Li R; Song T; Zhang N; Tallman AM; Guttman-Yassky E
    J Invest Dermatol; 2021 Jul; 141(7):1847-1851. PubMed ID: 33493530
    [No Abstract]   [Full Text] [Related]  

  • 10. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
    Dreyling M; Santoro A; Mollica L; Leppä S; Follows GA; Lenz G; Kim WS; Nagler A; Panayiotidis P; Demeter J; Özcan M; Kosinova M; Bouabdallah K; Morschhauser F; Stevens DA; Trevarthen D; Giurescu M; Cupit L; Liu L; Köchert K; Seidel H; Peña C; Yin S; Hiemeyer F; Garcia-Vargas J; Childs BH; Zinzani PL
    J Clin Oncol; 2017 Dec; 35(35):3898-3905. PubMed ID: 28976790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma.
    Cohen JB; Maddocks KJ; Huang Y; Christian BA; Jaglowski SM; Flowers CR; Blum KA
    Leuk Lymphoma; 2017 Sep; 58(9):1-2. PubMed ID: 28278718
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies.
    Kater AP; Tonino SH; Spiering M; Chamuleau MED; Liu R; Adewoye AH; Gao J; Dreiling L; Xin Y; Doorduijn JK; Kersten MJ;
    Blood Cancer J; 2018 Feb; 8(2):16. PubMed ID: 29434192
    [No Abstract]   [Full Text] [Related]  

  • 14. The JAK-STAT pathway: a therapeutic target in hematological malignancies.
    Ferrajoli A; Faderl S; Ravandi F; Estrov Z
    Curr Cancer Drug Targets; 2006 Dec; 6(8):671-9. PubMed ID: 17168672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Pilot Randomized Trial on Safety and Efficacy of a Novel Topical Combined Inhibitor of Janus Kinase 1/3 and Spleen Tyrosine Kinase for GVHD-Associated Ocular Surface Disease.
    Kheirkhah A; Di Zazzo A; Satitpitakul V; Fernandez M; Magilavy D; Dana R
    Cornea; 2017 Jul; 36(7):799-804. PubMed ID: 28445193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial treatment of B-cell prolymphocytic leukemia with ibrutinib.
    Moore J; Baran AM; Meacham PJ; Evans AG; Barr PM; Zent CS
    Am J Hematol; 2020 May; 95(5):E108-E110. PubMed ID: 31951033
    [No Abstract]   [Full Text] [Related]  

  • 17. Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
    Uckun FM; Qazi S
    Expert Rev Anticancer Ther; 2010 Sep; 10(9):1407-18. PubMed ID: 20836676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.
    Burke JM; Shustov A; Essell J; Patel-Donnelly D; Yang J; Chen R; Ye W; Shi W; Assouline S; Sharman J
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):e327-e331. PubMed ID: 29934062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in serum diamine oxidase activity during chemotherapy in patients with hematological malignancies.
    Tsujikawa T; Uda K; Ihara T; Inoue T; Andoh A; Fujiyama Y; Bamba T
    Cancer Lett; 1999 Dec; 147(1-2):195-8. PubMed ID: 10660106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promising new treatments for rheumatoid arthritis - the kinase inhibitors.
    Yazici Y; Regens AL
    Bull NYU Hosp Jt Dis; 2011; 69(3):233-7. PubMed ID: 22035435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.